At a glance
ClinicalIndex Comparison RecordN/ACompleted· 56 enrolled
Drug / intervention
Dexcom continuous glucose monitordevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Feasibility and Clinical Utility of the Dexcom G6 Continuous Glucose Monitoring Device for the Care of Patients With Type 2 Diabetes Not Using Insulin Therapy
In Brief
A clinical study evaluating Dexcom continuous glucose monitor for Type 2 Diabetes. Completed, enrolled 56 participants across 1 site.
Detailed Summary
The objective of this study is to evaluate the feasibility and clinical utility of a continuous glucose monitoring device (CGM, Dexcom G6) for the care of patients with type 2 diabetes who are on non-insulin therapies.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes
CountriesUnited States
CollaboratorsDexCom, Inc.
Timeline
N/ACompletedFinished
20222023202420252026
Enrollment StartJan 2022
First PostedAug 2022
Primary CompletionNov 2023
TodayJul 2026
First PostedAug 31, 2022
Enrollment StartJan 15, 2022
Primary CompletionNov 30, 2023
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 3.8 years ago
Interventions
Dexcom continuous glucose monitordevice
The investigational device used in this study is the Dexcom G6 Pro/Personal Continuous Blood Glucose Monitoring system.